Literature DB >> 23973891

Variants in interleukin family of cytokines genes influence clearance of high risk HPV in HIV-1 coinfected African-American adolescents.

Staci L Sudenga1, Howard W Wiener, Aditi Shendre, Craig M Wilson, Jianming Tang, Sadeep Shrestha.   

Abstract

Our work aimed to examine the potential influence of variants in interleukin/interleukin receptors genes on high-risk (HR-HPV) HPV clearance. Clearance of genital HR-HPV infection was evaluated for 134 HIV-1 seropositive African-American female adolescents from the Reaching for Excellence in Adolescent Care and Health (REACH) cohort. Genotyping targeted 225 single nucleotide polymorphisms (SNPs) within the exons, 5' untranslated region (UTR) and 3' UTR sequences of 27 immune-related candidate genes encoding interleukin family of cytokines. Cox proportional hazard models were used to determine the association of type-specific HPV clearance adjusting for time-varying CD4+ T-cell count and low-risk (LR-HPV) HPV co-infections. HR-HPV clearance rates were significantly (p < 0.001) associated with five SNPs (rs228942, rs419598, rs315950, rs7737000, and rs9292618) mapped to coding and regulatory regions in three genes (IL2RB, IL1RN, and IL7R). These data suggest that the analyzed genetic variants in interleukin family of cytokines modulate HR-HPV clearance in HIV-1 seropositive African-Americans that warrants replication.
Copyright © 2013 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23973891      PMCID: PMC3842375          DOI: 10.1016/j.humimm.2013.08.010

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  29 in total

Review 1.  Immune evasion in human papillomavirus-associated cervical cancer.

Authors:  Robert W Tindle
Journal:  Nat Rev Cancer       Date:  2002-01       Impact factor: 60.716

2.  Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women.

Authors:  L Ahdieh; A Muñoz; D Vlahov; C L Trimble; L A Timpson; K Shah
Journal:  Am J Epidemiol       Date:  2000-06-15       Impact factor: 4.897

3.  Human papillomavirus infection in women infected with the human immunodeficiency virus.

Authors:  X W Sun; L Kuhn; T V Ellerbrock; M A Chiasson; T J Bush; T C Wright
Journal:  N Engl J Med       Date:  1997-11-06       Impact factor: 91.245

4.  Key considerations and current perspectives of epidemiological studies on human papillomavirus persistence, the intermediate phenotype to cervical cancer.

Authors:  S L Sudenga; S Shrestha
Journal:  Int J Infect Dis       Date:  2013-02-27       Impact factor: 3.623

5.  The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research.

Authors:  Lara F Bratcher; Vikrant V Sahasrabuddhe
Journal:  Infect Agent Cancer       Date:  2010-05-12       Impact factor: 2.965

Review 6.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

7.  Cytokine and cytokine receptor single-nucleotide polymorphisms predict risk for non-small cell lung cancer among women.

Authors:  Alison L Van Dyke; Michele L Cote; Angie S Wenzlaff; Wei Chen; Judith Abrams; Susan Land; Craig N Giroux; Ann G Schwartz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-06       Impact factor: 4.254

8.  Interleukin 1 receptor antagonist (IL-1RA) polymorphism in women with cervical cancer.

Authors:  Alexander Mustea; Jalid Sehouli; Dominique Könsgen; Dirk Stengel; Dumitru Sofroni; Werner Lichtenegger
Journal:  Anticancer Res       Date:  2003 Mar-Apr       Impact factor: 2.480

9.  Single nucleotide polymorphisms in the PRDX3 and RPS19 and risk of HPV persistence and cervical precancer/cancer.

Authors:  Mahboobeh Safaeian; Allan Hildesheim; Paula Gonzalez; Kai Yu; Carolina Porras; Qizhai Li; Ana Cecilia Rodriguez; Mark E Sherman; Mark Schiffman; Sholom Wacholder; Robert Burk; Rolando Herrero; Laurie Burdette; Stephen J Chanock; Sophia S Wang
Journal:  PLoS One       Date:  2012-04-09       Impact factor: 3.240

10.  The impact of highly active antiretroviral therapy on prevalence and incidence of cervical human papillomavirus infections in HIV-positive adolescents.

Authors:  Sadeep Shrestha; Staci L Sudenga; Jennifer S Smith; Laura H Bachmann; Craig M Wilson; Mirjam C Kempf
Journal:  BMC Infect Dis       Date:  2010-10-14       Impact factor: 3.090

View more
  5 in total

Review 1.  Cancer prevention in HIV-infected populations.

Authors:  Priscila H Goncalves; Jairo M Montezuma-Rusca; Robert Yarchoan; Thomas S Uldrick
Journal:  Semin Oncol       Date:  2015-09-08       Impact factor: 4.929

2.  Meta-synthesis and science mapping analysis of HIV/HPV co-infection: a global perspective with emphasis on Africa.

Authors:  Hope Onohuean; Eric O Aigbogun; Bright E Igere
Journal:  Global Health       Date:  2022-03-24       Impact factor: 4.185

3.  Association between IL7R polymorphisms and severe liver disease in HIV/HCV coinfected patients: a cross-sectional study.

Authors:  María Guzmán-Fulgencio; Juan Berenguer; María A Jiménez-Sousa; Daniel Pineda-Tenor; Teresa Aldámiz-Echevarria; Pilar García-Broncano; Ana Carrero; Mónica García-Álvarez; Francisco Tejerina; Cristina Diez; Sonia Vazquez-Morón; Salvador Resino
Journal:  J Transl Med       Date:  2015-06-30       Impact factor: 5.531

Review 4.  Global Inequities in Precision Medicine and Molecular Cancer Research.

Authors:  Thomas M Drake; Stephen R Knight; Ewen M Harrison; Kjetil Søreide
Journal:  Front Oncol       Date:  2018-09-04       Impact factor: 6.244

5.  Dense genotyping of immune-related loci identifies variants associated with clearance of HPV among HIV-positive women in the HIV epidemiology research study (HERS).

Authors:  Staci L Sudenga; Howard W Wiener; Caroline C King; Anne M Rompalo; Susan Cu-Uvin; Robert S Klein; Keerti V Shah; Jack D Sobel; Denise J Jamieson; Sadeep Shrestha
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.